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Capsule:  In a retrospective study of patients with neurofibromatosis 1 undergoing PGD, 
only 37% of all biopsied embryos were confirmed to be unaffected by NF1 and at least 
27% of couples achieved a live birth.  
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ABSTRACT 
 
Objective: To examine the effect of patient and facility level factors on the success of 
pre-implantation genetic diagnosis (PGD) in patients with neurofibromatosis 1 (NF1) 
Design: Retrospective review  
Setting:  Large PGD reference laboratory 
Patients: All patients with NF1 referred between June, 2004 and May, 2013 
Main Outcome Measures: Embryos’ NF1 mutation status and live birth rates   
Results:  77 couples underwent 156 PGD cycles during the study period.  The average 
maternal age at time of embryo biopsy was 33.2 years,.  The majority of embryos had a 
day 3 single blastomere biopsy without aneuploidy screening. A diagnosis was obtained 
for 80% of biopsied embryos; 20% of biopsies were non-diagnostic due to technical 
failures.  Diagnosis was more often obtained for embryos of parents with familial disease 
and for embryos biopsied at centers which referred multiple NF1 cases.  Among 
diagnosed embryos, 483/1060 (46%) were unaffected by the parental NF1 mutation.  
22/156 (14%) of cycles had a confirmed live birth; if the observed success rate was 
applied to cycles with unknown outcomes, 33/156 (21%) of cycles are expected to have 
resulted in live birth.  In multivariate logistic regression, having a live birth was 
significantly associated with having more unaffected embryos available for transfer 
(OR=1.33 per additional embryo, 95% CI: 1.02-1.72). 
Conclusion:  Advances in biopsy and diagnostic techniques which increase the number 
of unaffected embryos may improve live birth rates for patients with NF1.  Clinicians 
should counsel patients about their fertility and reproductive options early, using disease-
specific data to set appropriate expectations for the PGD process.  
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INTRODUCTION 
 
 Preimplantation genetic testing is a molecular technique in which an embryo 
generated by in vitro fertilization (IVF) can be tested for a genetic condition prior to 
uterine transfer.(1)  By amplifying and examining genetic material from a cellular biopsy 
of the embryo, a laboratory can determine which embryos may carry certain genetic 
abnormalities, and doctors can implant only those embryos shown to be free of these 
abnormalities.(2)  Preimplantation genetic diagnosis (PGD) is used to analyze embryos 
for specific genetic mutations found in one or both parents, while preimplantation genetic 
screening (PGS) tests embryos for chromosomal aneuploidies.  Preimplantation genetic 
testing can be viewed as an early form of prenatal diagnosis and offers an alternative for 
couples who wish to increase their chances of giving birth to a healthy child, but are 
unwilling to terminate an affected pregnancy.(3)   
 Since its first application in preventing transmission of X-linked disorders(4) and 
cystic fibrosis,(5) PGD has become an increasingly popular technique for couples 
affected by monogenic disorders to reduce their risks of having a similarly affected child. 
(5,6)  In particular, the number of PGD analyses being performed for patients with cancer 
predispositions syndromes has been steadily increasing over the past decade.(7)   
 One such cancer predisposition syndrome is neurofibromatosis type 1 (NF1), an 
autosomal dominant, monogenic disorder that displays full penetrance.  NF1 is the most 
common neurogenetic condition (with a birth prevalence of approximately 1 in 
3000),(8,9) and the sixth most common monogenic disorder to be tested using PGD.(10) 
Clinical manifestations of NF1 include multiple benign nerve sheath tumors 
(neurofibromas), intellectual impairments, and bony abnormalities, and persons with NF1 
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have an increased risk of developing cancers such as sarcomas and gliomas.(11)  
Comprehensive genetic analysis of the NF1 gene has been available since 2000 (12) and 
current testing can identify a causative genetic alteration in >95% patients who meet 
established clinical criteria, allowing many couples affected by NF1 the opportunity to 
pursue PGD. 
Currently, there are limited data available about the outcomes of PGD for NF1 
patients.  Previous publications have documented aggregate outcomes of PGD for 
multiple monogenic diseases (10,13,14,15,16) and prior NF1-specific reports have been 
case series of a small number of patients.(17,18,19)  For this reason, we retrospectively 
evaluated the diagnostic and clinical outcomes for couples affected by NF1 who pursued 
PGD at a large international laboratory that provides PGD services. 
 
 
MATERIAL AND METHODS: 
We retrospectively reviewed the medical records of an international laboratory 
providing testing for couples who pursued PGD to reduce the risk of transmitting NF1.  
We included all couples with NF1 referred to laboratory from the start of NF1 testing 
until May 2013.    This research was reviewed by the Partners Institutional Review Board 
and determined to be non-human subjects research.   
 
PGD Protocol 
 Oocyte stimulation was conducted according to referring IVF center’s individual 
protocols.  Embryos were fertilized using intracytoplasmic sperm injection (ICSI) to 
minimize the risk of subsequent sample contamination from supernumerary sperm 
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embedded in the zona pellucida.  DNA diagnostic reports from a CLIA-approved 
laboratory and buccal swab samples from appropriate family members were sent to the 
laboratory to generate molecular probes via a standardized procedure.   
 Genetic material was obtained from embryos primarily by cleavage-stage biopsy 
of a single blastomere on day three of development (>95% of cases).  Biopsy procedures 
for PGS were identical to those used in PGD, and additional biopsies were not required 
when both procedures were performed.  Biopsy samples were transported in individual 
tubes in a lysis buffer by courier to the laboratory for PGD analysis prior to implantation 
of embryos.    
 Before 2010, PGD analysis began with direct amplification of the DNA from the 
diploid cell(s).  The cells were lysed and a PCR reaction was performed amplifying the 
genetic region in question from each cell.  An outer amplification reaction and an inner 
amplification reaction were performed to isolate the mutated region in the gene. All 
patient samples received after 2010 were subjected to whole-genome amplification 
(WGA) protocols, rather than direct amplification.  Samples were amplified using the 
BlueGnome SurePlex system. Biopsy samples underwent genomic amplification 
followed by locus-specific standard PCR of 2ul aliquots.  Six fully-informative, NF1-
flanking genomic markers were tested independently to determine the haplotype of each 
sample; this was done to evaluate the remote possibility of an intragenic recombination.  
After standard PCR of each locus, the amplified DNA was analyzed on an Applied 
Biosystems 3300 capillary electrophoresis instrument, with independent genotype 
analysis of each allele.  Genotypes were then compared to the haplotype of the gamete 
providers to determine the NF1 status of each embryo.   
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 For samples also undergoing PGS, amplified DNA was labeled and hybridized 
onto Illumina 24sure BAC microarrays.  Microarrays were washed and scanned, and 
single channel images were imported into Illumina software.  Fixed algorithms 
automatically determined whole chromosome gains and losses, while segmental 
chromosome deletions or duplications larger than 10Mbp were examined manually.  
Reports from NF1 PGD analysis, and if applicable, PGS analysis, were issued to the 
referring IVF center within 48 hours.  Pregnancy test and birth outcomes were voluntarily 
reported by IVF centers back to the diagnostic laboratory. 
 
Data Collection 
Demographics  
We collected demographic data on affected partner’s inheritance pattern for NF1 
(sporadic or familial), maternal and paternal age, gender of the affected partner, history of 
infertility, and prior use of IVF.  Referring IVF centers were categorized based on 
number of NF1 cases completed at this PGD laboratory by May, 2013 (single referral vs. 
multiple referrals) and on practice type (academic vs. non-academic affiliation).   
 
Embryo data collection 
We collected data on the number, quality, and stage (cleavage stage vs. 
trophectoderm) of all biopsied embryos within each IVF cycle for NF1 patients.  Embryo 
quality was rated by referring centers using a three-point, four-point, or five-point scale.    
For consistency in our analyses, four- and five-point ratings were rescaled to a three-point 
scale (good, fair, and poor).   
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Additional laboratory data retrieved included the NF1 status of each biopsied cell, 
and the diagnosis of aneuploidy for any cycles also being tested with PGS.  Embryos that 
displayed normal NF1 alleles were classified as unaffected, while embryos that displayed 
the mutant parental allele were considered affected.  If the laboratory report indicated 
amplification failure of the probe or no molecular signal, the outcome was classified as 
“insufficient data”.  Embryos were classified as “inconclusive results” if the laboratory 
report indicated allele drop-out, weak amplification, conflicting marker data, 
recombination, incomplete analysis, or multiple parental alleles observed.  Outcomes of 
PGS were classified as euploid, aneuploid, or no signal. 
 
Clinical outcomes 
We collected all available data on clinical outcomes for all PGD cycles, including 
pregnancy test results and occurrence of a live birth.  While clinical outcomes were not 
routinely collected by the reference laboratory (since all clinical care took place at the 
referring IVF center), many IVF centers voluntarily reported outcome data back to the 
laboratory.  Cycles which produced only affected and/or aneuploid embryos were 
assumed to not have led to transfer or live birth.  We also assumed no live birth occurred 
if a cycle resulted in a negative pregnancy test or the couple began a new PGD cycle 
within the following nine months.  Reasons for no live birth after positive pregnancy test 
were not available, but would include biochemical pregnancy, spontaneous abortions, and 
elective terminations.    
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Statistical analysis 
Factors related to ability to obtain a molecular diagnosis 
 Descriptive statistics of the patient cohort and embryo characteristics were 
tabulated.  If two biopsies were performed on the same embryo, the most informative 
diagnosis was used for analysis (i.e status as affected/unaffected rather than insufficient 
data or inconclusive result).  Chi-square analyses were used to test for an association 
between the ability to obtain a molecular diagnosis on an embryo (as either affected or 
unaffected with NF1) with the following variables: embryo quality rating, familial or 
sporadic mutation, number of NF1 referrals from IVF center, IVF practice type, and use 
of whole-gene amplification.   We excluded from these analyses seven samples which 
could not be analyzed due to breakage during shipping.  
 
Factors associated with PGD resulting in live birth 
Descriptive statistics were generated for the number of pregnancies and live births 
observed.  We also generated estimated pregnancy and birth rates, which took into 
account the likely outcomes of cycles with missing data in order to predict what the true 
pregnancy and birth rates may have been in our cohort.  To derive the estimated number 
of unobserved pregnancies, we multiplied the observed pregnancy rate in women with an 
embryo transfer by the number of cycles with unknown pregnancy outcome.  To derive 
the estimated number of unobserved live births, we multiplied the observed birth rate in 
pregnant women by the number of observed and unobserved pregnancies with unknown 
outcome.   
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We performed logistic regression analysis to determine which factors correlated 
with live birth.  Dependent variables included number of unaffected embryos produced, 
maternal age, number of NF1 referrals from the IVF center to this diagnostic laboratory,, 
and time elapsed since the first PGD analysis was performed (in months).  Time elapsed 
since the first PGD analysis was included in our statistical analysis to control for 
improvements in PGD and IVF technique over time.  We excluded from this analysis 24 
cycles which did not produce any unaffected embryos, 1 cycle for which embryo transfer 
was known not to have occurred, and 4 cycles with incomplete data on number of 
unaffected embryos produced.  
All statistical analysis was conducted using SAS version 9.2.   
 
RESULTS 
Patient demographics and clinic characteristics 
From June 2004, to May 2013, 81 couples affected by NF1 began the PGD 
process, and 77 couples completed at least one PGD cycles.  Three couples did not 
undergo an IVF cycle because molecular probes could not be generated for PGD analysis, 
and one couple underwent an IVF cycle but did not undergo PGD analysis because no 
embryos of sufficient quality for biopsy were produced.  A total of 156 PGD cycles were 
completed, with a median number of 2 cycles per couple (range, 1 - 9 cycles).  Thirty-
three couples (43%) completed one cycle, 24 (31%) completed two cycles, 12 (16%) 
completed three cycles, and 8 (10%) completed four or more cycles.  42 cycles (27%) 
were performed in women with advanced maternal age (age ≥35 years).  
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The affected partner was female in 51 couples (66%).  There were 48 sporadic 
NF1 patients (62%) and 23 familial patients (30%); the inheritance pattern was unknown 
or not reported in 6 patients (8%).  Fourteen (18%) couples had a history of infertility and 
4 (5%) had previously undergone IVF.  The average maternal and paternal age at the time 
of embryo biopsy was 33.2 years (range, 23.7-43.1 years) and 35.6 years (range, 25.8-
57.5 years), respectively.   
Couples were referred from 62 IVF centers from 18 U.S. states and 6 non-U.S. 
countries (Table 1).  51 centers referred one couple for NF1 PGD, and 11 centers referred 
more than 1 couple.  The clinic with the highest number of NF1 cases referred eight 
patients for PGD, seven of whom completed a PGD cycle.  14 IVF centers were 
academically affiliated, and 47 were independent IVF centers.  Throughout the nine years 
of data collection, the use of PGD by couples affected by NF1 steadily increased from 3 
in 2004 to a peak of 38 cycles in 2010. 
 
PGD Cycle Outcomes  
Over 156 PGD cycles, 1356 embryos were biopsied (Figure 1).  The median 
number of embryos biopsied per cycle was 8 (range, 1 to 40 embryos) for all women and 
was 6 (range, 1 to 13 embryos) for women of advanced maternal age (≥35 years).  34 
embryos (2.5%) were biopsied twice.  88% of biopsied embryos (1193/1356) were fresh, 
and 12% of biopsied embryos (163/1356) were frozen.  By IVF center self-report, 23% of 
biopsied cells were of good quality, 58% were of fair quality, 8% were of poor quality, 
and 11% were not rated.  Whole-genome amplification was used to analyze 782 embryos 
(within 90 cycles) and was not used in 574 embryos (within 66 cycles).    
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PGD outcomes were available for 1322/1356 (97%) of the biopsied embryos and 
a clear molecular diagnosis was obtained for 1060/1322 (80%) embryos.  Insufficient 
molecular data was observed in 161/1322 (12%) embryos and 101/1322 (8%) embryos 
produced inconclusive results.  Of the embryos with a molecular diagnosis, 483/1060 
(46%) were unaffected with NF1.  The number of unaffected embryos produced per PGD 
cycle ranged from 0 to 18, with a median number of 3 unaffected embryos per cycle.  
135/156 (87%) cycles produced at least one unaffected embryo. 
Definitive diagnoses were more likely to be obtained for embryos of parents with 
familial NF1 inheritance (84%) compared to embryos from parents with sporadic NF1 
(76%) (χ2=12.1, p<0.001).  Diagnoses were also more likely to be obtained for embryos 
biopsied at centers with multiple NF1 referrals (83%) compared to embryos biopsied at 
centers with a single NF1 referral (77%) [χ2=6.2, p=0.01].  The ability to obtain a 
molecular diagnosis was not associated with embryo quality rating (p=0.46), academic 
affiliation of the referring medical center (p=0.18), or use of whole-gene amplification in 
the probe development process (p=0.98). 
 
PGS cycle outcomes 
 Ten couples completing a PGD cycle also underwent PGS in a total of 15 cycles.  
The average maternal age for patients completing a cycle with PGS was 35.5 years 
(range, 29.9-42.0 years).  PGS was done in addition to PGD on 114 embryos. Of these, 
44/114 (39%) were euploid, 56/114 (49%) displayed some form of aneuploidy, and 
14/114 (12%) did not display a signal.  26 embryos unaffected by NF1 were not 
transferred due to the presence of aneuploidy.  In 3 cycles, even though embryos without 
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NF1 were produced, no embryos were available for transfer due to aneuploidies found 
during PGS.   
 
Pregnancy and birth outcomes 
132/156 (85%) cycles had at least one embryo suitable for transfer (Figure 2).  
Pregnancy test data were available for 80/132 (61%) cycles with at least one embryo 
suitable for transfer.  Of the cycles with pregnancy test data, 41/80 (51%) resulted in a 
positive serum pregnancy test.  In 22 cycles, these pregnancies resulted in a live birth.  
Multiple births (twin or triplet) accounted for 23% of the live births and a total of 28 
infants were born to 21 different couples.  No live birth occurred in 13/41 (32%) cycles 
with a positive pregnancy test, and there were no birth outcome available for the 
remaining 6/41 (15%) cycles.   
Overall, 21/77 (27%) of couples undergoing at least one IVF/PGD cycle achieved a live 
birth.  Among couples that successfully had a live birth, the median number of cycles to 
achieve a live birth was 2 (range, 1-5 cycles).  Of these couples, 19/21 (90%) were 
successful within their first two cycles of PGD.  By applying the observed pregnancy and 
birth rates to cycles for which an outcome was unknown, we estimate that 57/156 (37%) 
of cycles resulted in a positive pregnancy test, and that 33/156 (21%) of cycles resulted in 
a live birth (Table 2). 
 In multivariate logistic regression, having a higher number of unaffected embryos 
available for transfer was significantly associated with having a live birth after a given 
PGD cycle (p=0.03, OR=1.33 per additional embryo, 95% CI: 1.02 -1.72). Maternal age, 
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number of center referrals, and months since the first PGD analysis was performed were 
not significantly associated with birth outcome. 
 
Reasons for failure of PGD technology 
4/81(5%) couples affected by NF1 who wished to pursue PGD were not able to.  
Molecular probes could not be designed for three couples due to the specific nature of 
their de novo mutations.   When attempting to develop molecular probes, it was found 
that each patient’s specific mutation in the NF1 gene made it nearly identical to another 
area of DNA (called a pseudogene).  During PCR, both the NF1 gene and the pseudogene 
were amplified (known as pseudogene bleed-through), which can lead to embryos 
without the parental mutation presenting as false positives.  Without genetic samples 
available from other affected family members, the risk of false positive was deemed 
unacceptably high to continue PGD. Additionally, for one couple, no embryos of 
sufficient quality to biopsy were produced in the only IVF cycle undertaken. 
 
 
DISCUSSION: 
 In this study, we reviewed the records of one of the largest diagnostic laboratories 
in the United States to evaluate the outcomes of pre-implantation genetic diagnosis for 
patients affected by NF1.   This data provides valuable disease-specific information for 
counseling couples about the potential benefit of using IVF and PGD to reduce the risk of 
transmitting NF1 to their offspring.  The diagnostic laboratory was able to create 
molecular probes for most NF1 couples (95%).  Of 1322 biopsied embryos, 483 (37%) 
were determined to be unaffected by the parental NF1 mutation.  We estimate that 37% 
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of IVF/PGD cycles for NF1 result in a positive pregnancy test, and that 21% of all cycles 
result in a live birth.  At least 27% of couples eventually achieved at least one live birth 
during treatment. 
 Analysis of disease-specific outcomes after PGD is increasingly important as the 
scope of reproductive counseling spreads beyond women and men affected by infertility 
to include patients with genetic abnormalities.  In an age where the cost of genome 
sequencing is dramatically dropping, PGD is becoming available to more patient 
populations.  Between 1997 and 2007, parents used PGD in more than 10,000 IVF cycles 
to prevent the transmission of a known genetic disorder to a child.(7)  NF1 was the third 
most common autosomal dominant disorder analyzed among centers reporting to the 
European Society of Human Reproduction and Embryology (ESHRE) consortium in 
2008.(10)   For this reason, analysis of laboratory and clinical outcomes after PGD in 
patients with NF is needed to appropriately advise patients with NF1 about their 
reproductive options. 
  In our paper, 80% of biopsied embryos could be classified as affected or 
unaffected by the parental NF1 mutation.  This figure is slightly below the average figure 
observed between 1997 and 2007 for two other autosomal dominant disorders:  86.6% for 
myotonic dystrophy type 1 and 87.8% of Huntington’s disease.(7)  Given that the ability 
to identify the presence or absence of mutations for all monogenic disorders during PGD 
has improved from 83% in 1997 to 90% in 2007, it is likely that a higher percentage of 
embryos from couples affected by NF1 are able to be diagnosed today.(7)   
Definitive diagnoses were significantly more likely to be obtained for embryos 
from parents with familial NF1 inheritance compared to embryos from parents with 
  PGD Outcomes in NF1 
 15 
sporadic NF1 (i.e. parent was the first in their family to have an NF1 mutation).  In 
familial cases, genetic material could be solicited from additional family members, 
allowing for more sensitive probe preparation that allowed a greater diagnosis success 
rate.  Diagnoses were also more likely to be obtained for embryos biopsied at centers 
with multiple NF1 referrals compared to embryos biopsied at centers with a single 
referral.  This difference highlights the importance of consulting medical professionals 
experienced in PGD for the retrieval and biopsy of embryos. 
46% of embryos which were able to be diagnosed were unaffected with the 
parental NF1 mutation.  Because NF1 is autosomal dominant, it is expected that an 
average of 50% of embryos would be unaffected by the parental mutation.  However, in 
both our series and in prior analysis of ESHRE data on muscular dystrophy 1 (43.4%) 
and Huntington’s disease (43.9%)(10), there were fewer unaffected embryos than 
expected.  It is possible that technical difficulties in amplification and analysis are more 
frequent in unaffected samples, and that future improvements in laboratory analysis will 
increase the proportion of unaffected embryos observed.   
The proportion of PGD cycles that resulted in a live birth in our sample was lower 
than the proportion of successful IVF cycles reported by the Society for Assisted 
Reproductive Technology.  Given that many patients with NF1 and their partners do not 
have a history of infertility, patients may be surprised to learn that their reproductive 
chances are not equal to or even greater than other IVF couples (almost all of whom have 
experienced infertility).  If so, education regarding the implications of selecting embryos 
based on mutation status rather than morphology may be warranted. 
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While couples affected by NF1 pursuing PGD have lower success rates than 
couples with infertility only, analysis of clinical outcomes showed that a similar number 
of women in our cohort achieved a positive pregnancy test and live birth compared to 
women with other autosomal dominant and X-linked disorders (Supplemental Table 1).  
As expected, the pregnancy and birth rates for couples with NF1 and other autosomal 
dominant disorders are lower than those for autosomal recessive disorders(10), which are 
expected to have an average of 75% of embryos unaffected and available for transfer as 
opposed to 50%.  Thus, previously published data on PGD that has been aggregated 
across both dominant and recessive disorders will overestimate the success rate of PGD 
in NF1, and should not be used for comparison to our results. 
While the majority of embryos in our study were biopsied at the cleavage-stage, 
recent evidence suggest that higher live birth rates may be achieved with blastocyst stage 
biopsy of the trophectoderm.(20,21)  In a randomized controlled trial (2013), the adverse 
effect of cleavage stage biopsy compared to blastocyst biopsy was equivalent to two of 
every five reproductively competent embryos becoming incapable of sustained 
implantation.(20,22)  As such, increased adoption of blastocyst biopsy could lead to even 
higher live birth rates in NF1 couples attempting PGD in the future.   
 In multivariate analysis, the only factor significantly associated with having a live 
birth was having a larger number of unaffected embryos available for transfer (OR 1.33, 
[95% CI, 1.03 – 1.72].   This result is unsurprising, given that the more embryos to 
choose from for implantation, the higher likelihood there will be an optimally developing 
embryo available.  Our results agree with that from Grace et al (2006), who found that 
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only significant factor affecting live birth outcome was presence of two or more embryos 
genetically suitable for transfer.(23)  
 Our data may be useful in future studies to calculate the cost-effectiveness of 
PGD in preventing transmission of NF1 to future generations.   The average cost of an 
IVF cycle in the US is between $12,400 and $13,775.(24,25)  In addition, ICSI costs an 
additional $1500 per IVF cycle, and PGD costs between $2500-$5000 per cycle.(26)  
Given that the majority of couples in our study who achieved a live birth did so within 
the first 2 cycles, the direct medical costs of PGD compared to a natural birth are between 
$33,000 and $40,000.  Comparisons of this figure to the lifetime costs of caring for a 
child with NF1 will likely reveal a significant savings to insurance companies (at least in 
the United States) from covering PGD and associated IVF expenses.  Future cost-
effectiveness analyses are imperative to investigate the impact of PGD on the care of NF1 
and other genetic disorders.  
 There were limitations to our study due to its retrospective nature.  There was 
missing data regarding pregnancy test and birth outcomes, and no data available on 
clinical pregnancy rates.  For this reason, we report the possible range of outcomes 
possible (from the number of births actually observed, to the highest possible number of 
births if all missing data was positive).  In addition, our analysis spanned from 2004 to 
2013, and while timing was not significant in our analysis of birth outcomes, our results 
may not reflect the outcomes that are obtained in current practice.  Current use of 
blastocyst-stage (rather than cleavage-stage) biopsy in particular may result in more 
favorable outcomes than those reported in this series. 
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While having all cases from a single reference laboratory meant that probe 
preparation and analysis protocols were identical, there may be many differences between 
referring IVF centers that would affect live birth rates, including ovarian stimulation 
protocols.  Similarly, our classification of centers based on number of NF1 case referrals 
is a crude marker of a center’s volume of PGD cases.   We recognize that centers that 
referred only one NF1 case to this diagnostic laboratory may have referred other cases to 
other laboratories, and the analysis of centers may be confounded by other systematic 
differences between the two groups. For this reason, our finding that centers with more 
case referrals have higher success rates should be validated using stricter criteria.  
Finally, while embryo quality rating was transformed to a single numerical scale from 
primary data, the ratings were determined by each referring IVF center.  This lack of 
standardization may have prevented us from recognizing an association between embryo 
quality and the ability to obtain a diagnosis on the embryo biopsy.   
 
CONCLUSIONS: 
 For many patients with NF1, PGD is an attractive option for starting a family.  
PGD is a useful for couples who want to avoid passing NF1 to the next generation, and 
are not amenable to alternative methods of prevention (such as prenatal diagnosis 
followed by elective termination or use of donor gametes).  While less than half of 
patients in our dataset achieved a live birth, strategies that increase the number of 
unaffected embryos produced and identified in each cycle could improve live birth rates 
in the future.  Identification of the optimal timing of embryo biopsy as well as laboratory 
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improvements that decrease the rate of non-informative biopsy results should be 
especially helpful.  
In addition, medical providers and genetic counselors should discuss PGD and 
with couples early in the care process, so they have time to consider their reproductive 
preferences before starting a family.  While overall pregnancy and birth rates were 
similar to other autosomal dominant disorders, our analysis revealed several factors that 
differ between NF1 and other disorders, as well as within NF1 patients.  Clinicians can 
use this disease-specific data to guide their discussion with patients to provide more 
tailored advice and to set realistic expectations of the PGD process.  
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Figures 
 
Figure 1: Diagnostic outcomes of PGD for neurofibromatosis 1. 
 
 
 
1Includes probe amplification failure or no molecular signal  
2Includes allele drop-out, conflicting marker data, multiple parental alleles observed, or 
recombination 
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Figure 2:  Clinical outcomes after PGD for neurofibromatosis 1 
 
 
1Includes biochemical pregnancy, spontaneous abortion, and/or elective termination 
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Table 1. Patient Demographics 
 N (%) 
Couples completing PGD analysis       77 
Maternal age (mean ± SD), years (range) 
Paternal age (mean ± SD), years (range) 
33.2 ± 4.2 (23.7-43.1) 
35.6 ± 6.0 (25.8-57.5) 
Advanced Maternal Age 
Mothers of advanced maternal age (>35 years)  
Mothers not of advanced maternal age 
 
21 (27%) 
56 (73%) 
Affected Partner 
Mother                                                               
Father                                                             
 
51 (66%) 
26 (34%) 
Inheritance Pattern 
Sporadic                                                            
Familial                                                              
Unknown, not reported                                       
 
48 (62%) 
23 (30%) 
  6 (8%) 
History of infertility 
 Present 
Male factor                                                    
Idiopathic                                                                 
Anovulatory 
Endometriosis   
Other  
None 
Unknown 
 
14 (18%) 
   8 
3
   1 
   1 
   1 
49 (64%) 
14 (18%) 
History of IVF  
Prior IVF  
For infertility 
For PGD 
Unknown reason 
None 
Unknown  
 4 (5%) 
   1 
   1 
   2 
61 (79%) 
12 (16%) 
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 Table 2. Clinical outcomes of IVF/PGD cycles for NF1 
 
 
 
  
 Observed Estimated 
Number of cycles with embryo biopsy 
     Cycles resulting in positive pregnancy test 
     Cycles resulting in live birth 
Number of cycles with embryo transfer 
     Cycles resulting in positive pregnancy test 
     Cycles resulting in live birth 
Percentage of live births with twins or triplets 
156 
   41 (26%) 
   22 (14%) 
132 
   41 (31%) 
   22 (17%) 
5 (23%) 
156 
   57 (37%) 
   33 (21%) 
132 
   57 (43%) 
   33 (25%) 
7 (21%) 
    PGD Outcomes for NF1 
   
Supplemental Table 1. Comparison of NF1 pregnancy outcomes after PGD (this manuscript) with published data from the European 
Society of Human Reproduction and Embryology (Goossens et al, 2012). 
 
Inheritance Type Autosomal Dominant Autosomal 
Recessive 
X-linked 
Condition studied NF11 Myotonic 
dystrophy 
type 1 
Huntington’s 
Disease 
Multiple 
disorders2 
Multiple 
disorders2 
Multiple 
disorders 
Time Period 2004-2013 1997-2007 1997-2007 2008 2008 2008 
Mean maternal age (years) 33.2 32 31 34 34 33 
Number of cycles w/ biopsy 156 552 516 543 401 223 
   Positive Pregnancy Test 26-37% 26% 28% 28% 40% 28% 
   Clinical Pregnancy --- 19% 22% 21% 30% 27% 
   Live birth 14-21%1 ---- --- 18%-19% 24%-29% 19% 
Number of cycles w/ 
embryo transfer 
132 445 421 423 361 171 
   Positive Pregnancy Test 31-43% 32% 34% 35% 45% 36% 
   Clinical Pregnancy --- 24% 26% 27% 33% 36% 
   Live birth 17-25% --- --- 23-25% 27%-32% 25% 
 
 
1 Ranges represent observed and estimated results in the current study.  
2  Ranges represent lower and upper limits of possible results, given the amount of missing data.  
 
 
